Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 crisaborole ointment versus vehicle in Chinese and Japanese patients with mild to moderate atopic dermatitis
2021-006538-38Phase 3
- Sponsor
- Pfizer
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Crisaborole ointment 2% with Vehicle (2 arms). Primary endpoint: Percent change from baseline in Eczema Area and Severity Index total score.
02
Drugs
crisaborole
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2021-006538-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006538-38.